Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure;Tratamiento de la hiperfosfatemia con sevelamer en pacientes con insuficiencia renal crónica avanzada

Nefrologia

Volumn 24, Issue 2, 2004, Pages 142-148

  Suner M ^a,b   Guerrero, A ^a   Montes, R ^a   Rivera, M ^a   Ruiz, A ^a   Martinez Garcia M ^a   Perez Valdivia M A ^a   Mateos, J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Esperanza Trinidad   (Spain)

Author keywords

Hyperphosphatemia; Lipid lowering drugs; Phosphate binders; Sevelamer hydrochloride

Indexed keywords

ANTILIPEMIC AGENT; BICARBONATE; CALCITRIOL; CALCIUM; CREATININE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; SIMVASTATIN; UREA; CHELATING AGENT; EPOXIDE; POLYAMINE; POLYETHYLENE DERIVATIVE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE CLEARANCE; DATA ANALYSIS; DIALYSIS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; PARAMETER; QUANTITATIVE ANALYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; ACID BASE BALANCE; BLOOD; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; DRUG SCREENING; GASTROINTESTINAL DISEASE; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; MIDDLE AGED; PATIENT ATTITUDE; RETROSPECTIVE STUDY; REVIEW;

ACID-BASE EQUILIBRIUM; ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; BICARBONATES; CALCIUM; CHELATING AGENTS; DRUG EVALUATION; DRUG THERAPY, COMBINATION; EPOXY COMPOUNDS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PATIENT ACCEPTANCE OF HEALTH CARE; PHOSPHATES; POLYAMINES; POLYETHYLENES; RETROSPECTIVE STUDIES;

EID: 3142737834     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 33: 694-701, 1999.
2. Cannata-Andía JB, Rodríguez-García M: Hyperphosphatemia as a cardiovascular risk factor-how to manage the problem. Nephrol Dial Transplant 17 (Supl. 11): 16-19, 2002.
3. Fernández E: El «asesino silencioso» actúa temprano. Nefrología XXIII: 377-380, 2003.
4. Martínez I, Saracho R, Ocharán J, Muñoz RI, Montenegro J: Papel de la dieta en el manejo de la osteodristrofia en la insuficiencia renal progresiva. Nefrología XXII (Supl. 2): 57-63, 2003.
5. Aresté N, Amor J, Cambil T, Salgueira M, Sánchez-Palencia R, Páez C, Gómez O, Palma A: Tratamiento precoz del hiperparatiroidismo secundario en la insuficiencia renal moderada: dieta baja en fósforo frente a carbonato cálcico. Nefrología XXII (Supl. 2): 64-68, 2003.
6. Hartmut H, Malluche, Mawad H: Management of hyperphosphatemia of chronic kidney disease: lesons from the past and future directions. Nephrol Dial Transplant 17: 1170-1175, 2002.
7. Amor J, Palma A: Manejo de la hiperfosforemia. Nefrología Vol. XXII (Supl. 2): 91-99, 2003.
8. Goodman WG, Goldin J, Guisan BD, Ion C, Gales B, Jider D, Wang Y, Chung J, Emerik A, Greaser L, Elashoff RM, Saludky IB: Coronary-artery calcification in young adult with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (20): 1478-1783, 2000.
9. Guérin AP, London CM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021, 2000.
10. Bleyer AJ: Phosphate binder usage in kidney failure patients. Expert Opin Pharmacother 4: 941-947, 2003.
11. Slatopolsky EA, Burke SK, Dillon MA, and the Renagel Study Group: Renagel, a nonabsorbed calcium- and aluminium-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 55: 299-307, 1999.
12. Chertow GM, Burk SK, Dillon MA, Slatopolsky E: Long-term effects of sevalmer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14: 2907-1914, 1999.
13. Bleyer AJ, Burke SK, Dillon M, Garrett MB, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in haemodialysis patients. Am J Kidney Dis 33 (4): 694-701, 1999.
14. Sadek T, Mazouz H, Bahloul H, Oprisiu R, Esper NE, Boitte F, Brazier M, Moriniere P, Fournier A: Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomised study. Nephrol Dial Transplant 18: 582-589, 2003.
15. Castro R, Heman A, Ferreir C, Travassos F, Numes-Azevedo J, Oliveira M: Renagel efficacy in severe secondary hyperparathyroidism. Nefrología XXII (5): 448-455, 2002.
16. Hervás JG, Prados D, Cerezo S: Treatment of hyperphosphatemia with sevelamer hydrochloride in haemodialysis patients: a comparison with calcium acetate. Kidney Int 63 (Supl. 85): S69-S72, 2003.
17. Chertow GM, Burke SK, Raggi P for the treat to goal working group: sevelamer attenuates the progression of coronary and aortic calcification in haemodialysis patients. Kidney Int 62: 245-252, 2002.
18. Borras M, Marco MP, Fernandez E: Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Peritoneal Dial Int 22 (6): 1776-1777, 2002.
19. Ortiz A, Ríos F, Melero R, Reyero A, Gazapo R, Casado S: Experiencia con sevelamer en diálisis peritoneal. Nefrología XXIII: 432-466, 2003.
20. Zucchelli P, Santoro A: Inorganic phosphate removal during different dialytic procedures. Int Artif Organs 10: 173-178, 1987.
21. Fournier A, Barsoum J, Fickl R, Oprisiu R, El Esper N, Moriniere P: Sevelamer, CaxP product and vitamin D. Nephrol Dial Transplant 16: 4239-430, 2001.
22. Nagano N, Miyata S, Obana S, Kobayashi N, Abe M, Fukushima N, Wada M: Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats. Nephrol Dial Transplant 18 (Supl. 3): iii81-iii85, 2003.
23. Tamashiro M, Iseki K, Sunagwa O, Inoue T, Higa S, Afuso H, Fukiyama K: Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 38: 64-69, 2001.
24. Gallieni M, Cozzolino M, Brancaccio D: Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int 57 (letter): 1776-1777, 2000.
25. Marco MP, Muray S, Betriu A, Craver L, Blart M, Fernández E: Treatment with sevelamer decreases bicarbonate levels in haemodialysis patients. Nephron 92: 499-500, 2002.